Home / Reports

Reports

Payers in US expect biosimilars to reduce costs

Payers in the US expect the use of biosimilars to be a strategy that can be used to reduce the cost of specialty drugs, according to a report published by biotech giant Amgen.

Prices of brand-name drugs in the US have doubled since 2011

According to Express Scripts, the average price of brand-name drugs in the US has doubled in the past five years and has increased on average by 16.2% since 2015. Express Scripts, the largest pharmacy benefit management organization in the US, based its March 2016 report on prescription use data for members with drug coverage by the organization.

Price/access expected to be major drivers for biosimilars uptake

Payers in the US expect price/access to be the major drivers for biosimilars uptake, according to a report published by biotech giant Amgen.

Pivotal clinical trials for infliximab biosimilars

Biosimilars of Johnson & Johnson’s blockbuster arthritis drug Remicade (infliximab), a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-α), are currently under development.

Pivotal clinical trials for etanercept biosimilars

Biosimilars of Amgen/Pfizer’s blockbuster arthritis drug Enbrel (etanercept), a fusion protein produced by recombinant DNA, are currently under development.

Pivotal clinical trials for adalimumab biosimilars

Biosimilars of AbbVie’s Humira (adalimumab), a human monoclonal antibody, are currently under development.

Biosimilar events from 2013 to 2015

During the period of 2013 to 2015, biosimilars has been increasingly on the agenda around the world.  Biosimilars are making steady progress, as can be seen by the increasing number of events, including approvals for biosimilars around the world [1].

Payers in US getting ready for biosimilars

Payers in the US are getting ready for the advent of biosimilars, according to a report published by biotech giant Amgen.

Payers in US view biosimilars as a lower-cost branded option

Payers in the US do not expect the biosimilars market to be like the generics market and they also do not expect the US biosimilars market to be like that in Europe, according to a report published by biotech giant Amgen.

Impact of antidepressant generics in Europe

Use of generic antidepressants may improve adherence and reduce the cost of pharmacotherapy for depression in European countries, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).